Multimeric Biotherapeutics, Inc.
October 17, 2023
Multimeric Biotherapeutics, Inc. is an early-stage, founder-backed company focused on stimulating immunity against cancer and infections. Its patented FortiVac technology elicits very strong CD8+ T cell responses that can be directed against cancer and infectious agents.
CEO/Top Company Official
Richard S. Kornbluth, MD, PhD
Lead Product in Development
FortiVac vaccine platform technology to elicit CD8+ T cells against cancer and infections.
Number Of Unlicensed Products